Form 4 for EDIT Editas Medicine, Inc.
Accepted 2022-02-11 00:00:00 ET · period of report 2022-02-10 · accession 0001415889-22-001224 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-11 | 2022-02-10 | EDIT | Shearman Mark S | EVP, CSO | A - Grant | $0.00 | +31.7K | 73.5K | +76% | $0 |
| D | 2022-02-11 | 2022-02-10 | EDIT | Shearman Mark S | EVP, CSO | A - Grant | $0.00 | +93.4K | 93.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-10 | A | A | 31,709 | $0.00 | 73,494 | D | — | — | (F1) The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 10, 2023 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 10, 2026. |
| 2 | Derivative | Stock Option (right to buy) | 2022-02-10 | A | A | 93,398 | $0.00 | 93,398 | D | $17.29 · — to 2032-02-09 | 93,398 Common Stock | (F2) This option was granted on February 10, 2022 and is scheduled to vest over four years in equal monthly installments beginning on March 10, 2022 through February 10, 2026. |